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Infectious keratitis (IK) is the 5th leading cause of blindness globally. Broad‑spectrum topical 
antimicrobial treatment is the current mainstay of treatment for IK, though adjuvant treatment 
or surgeries are often required in refractory cases of IK. This systematic review aimed to examine 
the effectiveness and safety of adjuvant amniotic membrane transplantation (AMT) for treating 
IK. Electronic databases, including MEDLINE, EMBASE and Cochrane Central, were searched for 
relevant articles. All clinical studies, including randomized controlled trials (RCTs), non‑randomized 
controlled studies and case series (n > 5), were included. Primary outcome measure was time to 
complete corneal healing and secondary outcome measures included corrected‑distance‑visual‑acuity 
(CDVA), uncorrected‑distance‑visual‑acuity (UDVA), corneal vascularization and adverse events. A 
total of twenty‑eight studies (including four RCTs) with 861 eyes were included. When compared to 
standard antimicrobial treatment alone, adjuvant AMT resulted in shorter mean time to complete 
corneal healing (− 4.08 days; 95% CI − 6.27 to − 1.88; p < 0.001) and better UDVA (− 0.26 logMAR; − 0.50 
to − 0.02; p = 0.04) at 1 month follow‑up in moderate‑to‑severe bacterial and fungal keratitis, with 
no significant difference in the risk of adverse events (risk ratio 0.80; 0.46–1.38; p = 0.42). One RCT 
demonstrated that adjuvant AMT resulted in better CDVA and less corneal vascularization at 6 months 
follow‑up (both p < 0.001). None of the RCTs examined the use of adjuvant AMT in herpetic or 
Acanthamoeba keratitis, though the benefit was supported by a number of case series. In conclusion, 
AMT serves as a useful adjuvant therapy in improving corneal healing and visual outcome in bacterial 
and fungal keratitis (low‑quality evidence). Further adequately powered, high‑quality RCTs are 
required to ascertain its therapeutic potential, particularly for herpetic and Acanthamoeba keratitis. 
Future standardization of the core outcome set in IK‑related trials would be invaluable.
Corneal infection or infectious keratitis (IK) is the most common cause of corneal blindness worldwide, particu-
larly in the developing  countries1. The incidence was estimated at 2.5–799 per 100,000 population/year1. It is a 
painful and potentially blinding ocular emergency that often requires hospital admission for intensive medical 
and/or surgical treatment. Depending on the geographical and temporal variations and population-based risk 
factors (e.g. agricultural practice, trauma, use of contact lens and others), bacteria and fungi have been shown 
to be the main causative microorganisms for IK, followed by viruses, parasites and polymicrobial  infection2–7. 
Broad-spectrum topical antimicrobial therapy is currently the gold standard for managing IK in routine clinical 
practice, though eye-saving procedures such as corneal gluing, therapeutic photoactivated chromophore-corneal 
cross-linking (PACK-CXL), amniotic membrane transplantation (AMT), and therapeutic keratoplasty may be 
required in recalcitrant  cases8–14.
Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-
bolically active epithelium, a thick basement membrane, and an avascular stromal  matrix15. It has been shown 
to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and 
anti-angiogenic properties, amongst  others8. In addition, the wide availability of AM donor tissues, lack of graft 
rejection and improvement in the storage methods have rendered AMT a popular choice of treatment for ocular 
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surface diseases. So far, AMT has been utilized to treat neurotrophic keratopathy, IK, corneal perforation, limbal 
stem cell deficiency, chemical eye injury, radiation keratopathy, bullous keratopathy, and many other ocular 
surface  conditions8,16–23.
To date, a number of studies have evaluated the benefit of AMT for treating active IK, though the majority 
of them were of small case series or case reports. In clinical practice, AMT is usually reserved as a second-line 
therapy in IK, mainly to promote cornea healing in non-healing ulcer after the sterilization phase. Therefore, the 
value of employing AMT in addition to standard antimicrobial treatment (SAT) during the active phase of IK 
remains uncertain. Liu et al24 recently conducted a systematic review of 17 studies on the use of AMT for infec-
tive and non-infective corneal ulcers. Although the review provided a detailed analysis on the corneal healing 
rate and visual improvement rate associated with the use of AMT, it did not compare the effect of adjuvant AMT 
and SAT with SAT alone. Furthermore, the study did not include several important relevant studies, including 
three randomized controlled trials (RCTs)25–27 and one non-randomized controlled study (NRCS)28, render-
ing the robustness of evidence uncertain. In light of these limitations, we conducted a systematic review and 
meta-analysis to critically examine the effectiveness and safety of combined AMT and SAT versus SAT alone in 
treating patients with IK.
Results
Literature search and study characteristics. The electronic searches last conducted on 01 November 
2020 retrieved a total of 969 titles and abstracts (see Fig. 1 for the PRISMA flow chart). After removing 262 
duplicates and including three additional records identified through other sources, the remaining 709 records 
were screened and 669 references that were not relevant to the scope of the review were excluded. A total of 35 
Figure 1.  PRISMA flow diagram of the literature search for assessing the evidence of amniotic membrane 
transplantation for infectious keratitis.
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full-text copies of papers were assessed for eligibility. After excluding seven ineligible articles, 28 studies were 
included in the systematic review. These included four  RCTs25–27,29, three  NRCSs28,30,31, and 21 case  series32–52, 
examining the efficacy and safety of AMT in 861 eyes with IK, of which 666 eyes received combined AMT with 
SAT and 195 eyes received SAT alone.
The causative microorganisms in the treatment group of AMT with SAT included 240 (36.0%) fungi, 199 
(29.9%) bacteria, 152 (22.8%) herpes viruses, 9 (1.4%) Acanthamoeba, 18 (2.7%) mixed, and 48 (7.2%) unspeci-
fied IK (either bacteria, fungi or mixed infection). The main characteristics of all RCTs and NCRSs, including 
the authors’ name, year of publication, number of treated eyes, types of causative microorganisms, severity of IK, 
types and techniques of AMT, main outcomes, and adverse events are summarized in Tables 1 and 2, respectively. 
Outcomes of RCTs are analyzed and summarized under the meta-analysis section.
Meta‑analysis of eligible RCTs. Overall description. Four eligible RCTs were included in the meta-
analysis, which included a total of 209 eyes that compared the effectiveness of SAT and adjuvant AMT with SAT 
 alone25–27,29. These consisted of four single-centre RCTs conducted separately in China (n = 2)27,29, India (n = 1)26, 
and Iran (n = 1)25. Two additional RCTs were also identified but were excluded from the meta-analysis as one 
RCT compared AMT with conjunctival  flap53 and another RCT compared AMT and argon laser treatment with 
AMT for treating  IK54. There was no ongoing trial identified from the clinical trial registry databases. The RCTs 
included participants with an average age between 45.5 and 55.6 years (ranged 15–98 years) with a slight (61.7%) 
male preponderance. None of the RCTs were prospectively registered with any clinical trial database.
Types of microbes and severity of IK. The four RCTs (n = 209 eyes) included a total of 108 (51.7%) eyes with 
bacterial keratitis, 95 (45.5%) eyes with fungal keratitis and 6 (2.9%) eyes with mixed bacterial/fungal keratitis. 
No herpetic or Acanthamoeba keratitis was included in any of the RCTs. Li et al.29 and Zeng et al.27 included 
only fungal keratitis and Tabatabaei et  al.25 included only bacterial keratitis whereas Arya et  al.26 included a 
mixed cohort, which included bacterial, fungal or mixed bacterial/fungal keratitis. The proportion of the types 
of microorganisms was similar between the treatment and control groups among all RCTs.
The baseline reporting and extent of the severity of IK were heterogeneous among the four RCTs. Two studies 
reported the baseline ulcer diameter or area in continuous  values25,27, one study reported the baseline severity 
in categorical values (i.e. 1–2 mm, 2–5 mm, or > 5 mm in diameter)26, and one study did not report the baseline 
severity of  IK29. Tabatabaei et al.25 and Zeng et al.27 included IK cases with a mean ulcer diameter of 5.2 mm 
and 6.7 mm, respectively (i.e. severe IK based on previous studies)55,56. Similarly, Arya et al.26 included mainly 
moderate-to-severe IK, with 47.5% of moderate ulcer (2–5 mm in diameter) and 42.5% of severe ulcer (> 5 mm 
in diameter). None of the RCTs included eyes presented with threatened or actual corneal perforation.
Surgical technique and timing of AMT. In terms of the preservation technique, two RCTs utilized cryopreserved 
 AMs26,27, one RCT utilized freeze-dried  AMs29, and one did not report the type of AMs used. Three  RCTs26,27,29 
employed AMT as an overlay patch (single- or double-layer) whereas one RCT 25 employed AMT as an inlay graft 
(double-layer). All AMTs were performed with the epithelium/basement membrane side up. The time interval 
between the initial presentation of IK and AMT was 3 days in one  study29, 2–5 days in one  study25, and unspeci-
fied in two  studies26,27.
Risk of bias. The risk of bias of the RCTs, based on the five abovementioned domains, is summarized in Fig. 2. 
Only one RCT 25 clearly reported the randomization process, with details on randomization and allocation con-
cealment. All RCTs had complete or nearly complete (> 99%) follow-up data. There were some concerns about 
the measurement of the outcome as it was not possible to mask the outcome assessor (i.e. AMT would be visible 
on postoperative clinical examination, hence revealing the intervention arm). In addition, there were some con-
cerns about selective reporting of outcomes across all RCTs as none of them were prospectively registered with 
any publicly accessible clinical trial database; therefore, the risk of bias could not be confidently evaluated. No 
relevant conflict of interest was declared in any of the RCTs.
The risk of bias of NRCS was assessed using the ROBIN-I tool. Two  NRCS28,31 were judged to be at serious risk 
of bias due to bias in selection of participants and measurement of outcomes. One  NRCS30 was judged to be at 
critical risk of bias due to baseline confounding, bias in selection of participants and measurement of outcomes.
Effects of intervention. The effects of interventions were categorized into: (A) time to complete corneal heal-
ing (defined by complete corneal re-epithelialization and resolution of infection); (B) UDVA and CDVA (in 
logMAR) at 1–6 months follow-up; (C) size of ulcer or infiltrate; (D) extent of corneal neovascularization at 
1–6 months; and (E) adverse events defined by worsening IK, endophthalmitis or corneal perforation requiring 
corneal gluing, tectonic keratoplasty or evisceration during the follow-up period. The GRADE summary of find-
ings for each treatment outcome is summarized in Table 3.
Time to complete corneal healing. Three RCTs (n = 169 eyes) reported the primary outcome measure, which 
was the time to complete corneal  healing25,27,29. There is very low-quality evidence that adjuvant AMT expedited 
the time to complete corneal healing compared to SAT alone [mean difference (MD) − 4.08 days; 95% CI − 6.27 
to − 1.88;  I2 = 18%; p < 0.001; Fig. 3A]. The quality of evidence was downgraded due to the high risk of bias and 
imprecision. The randomization process was not clear in one RCT 27 and allocation concealment were not per-
formed in two  RCTs27,29. Furthermore, there was lack of blinding of the participants and the assessors across all 
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three  RCTs25,27,29. In addition, the total number of participants/eyes pooled in the meta-analysis was less than the 
number generated by a conventional sample size calculation.
Uncorrected-distance-visual-acuity (UDVA). Two RCTs (n = 119 eyes) reported the UDVA at 1 month follow-
up25,27. There is very low-quality evidence that adjuvant AMT resulted in better UDVA compared to SAT alone 
(MD − 0.26 logMAR; − 0.50 to − 0.02;  I2 = 0; p = 0.04; Fig. 3B). The quality of evidence was downgraded due to 
high risk of bias and imprecision. The randomization process and allocation concealment were not clear in one 
RCT. There was lack of blinding of the participants and assessors and the sample size was limited in both RCTs. 
Only one RCT (n = 99 eyes) reported the UDVA at 6 months follow-up, where the adjuvant AMT group achieved 
a better UDVA than the SAT alone group (1.34 ± 0.69 vs. 1.69 ± 0.54; p < 0.001)25.
Corrected-distance-visual-acuity (CDVA). Only one RCT (n = 99 eyes) reported the CDVA at 1–6 months fol-
low-up, therefore meta-analysis was not  possible25. There is low-quality evidence that adjuvant AMT resulted in 
better CDVA (in logMAR) at 1 month (1.44 ± 0.75 vs. 1.74 ± 0.61; p < 0.001), 3 months (1.23 ± 0.72 vs. 1.65 ± 0.56; 
p = 0.007), and 6 months follow-up (1.13 ± 0.68 vs. 1.55 ± 0.59; p < 0.001). This RCT evaluated only bacterial kera-
titis, but not other types of microorganism. The quality of evidence was downgraded due to some risk of bias 
(lack of blinding) and imprecision (limited sample size).
Size of ulcer or infiltrate. We did not identify any RCT that reported the size of ulcer or infiltrate. However, 
one RCT (n = 99 eyes) reported the area of corneal scarring (in  mm2) at 6 months follow-up, which was found 
to better in the adjuvant AMT group than the SAT alone group (17.6 ± 5.7 vs. 22.8 ± 6.1; p < 0.001)25. The quality 
of evidence was downgraded due to some risk of bias (lack of blinding) and imprecision (limited sample size).
Corneal vascularization. Only one RCT (n = 99 eyes) reported the extent of corneal vascularization, measured 
as % of the total area of corneal surface, at 1–6 months follow-up25. There is low-quality evidence that adjuvant 
AMT resulted in less corneal vascularization (%) at 1  month (5.0 ± 4.0 vs. 7.0 ± 5.0; p < 0.001) and 6  months 
follow-up (2.0 ± 3.0 vs. 7.0 ± 6.0; p < 0.001). The quality of evidence was downgraded due to some risk of bias 
(lack of blinding) and imprecision (limited sample size).
Adverse events. All four RCTs (n = 209 eyes) reported the occurrence/risk of adverse events, defined as wors-
ening of IK or perforation requiring corneal gluing or tectonic  keratoplasty25–27,29. There is very low-quality 
evidence that there was no evidence of difference in the risk of adverse events between adjuvant AMT and SAT 
alone groups at 1–6 months follow-up (RR 0.80; 95% CI 0.46–1.38;  I2 = 0; p = 0.42; Fig. 3C). The risk of adverse 
events was noted to be considerably variable across four RCTs, with a risk ranging between 0.0 and 26.5% in 
Table 1.  Summary of all randomized control trials evaluating the effectiveness and safety of adjuvant amniotic 
membrane transplantation (AMT) for infectious keratitis. B bacteria; F fungi, A acanthamoeba, V viruses, 
M mixed infection, COI conflict of interest, NR Not reported. *Prospective registration of the clinical trial 
protocol in a publicly accessible database. $ Severity of the corneal ulcer is presented either in maximum linear 
diameter (mm) or in area  (mm2).
Authors Year
Protocol 





Causative organisms (in AMT group)
B F A V M
Arya et al.21 2008 N
Mean = 41.8 
(AMT) versus 
50.8 (control)
33 (83%) 20 20 5 12 0 0 3
Li et al.33 2014 N
Mean = 43.8 
(AMT) versus 
47.0 (control)
36 (72%) 25 25 0 25 0 0 0
Tabatabaei 
et al.20 2017 N
Mean = 48.3 
(AMT) vs. 43.4 
(control)
46 (46%) 49 50 49 0 0 0 0
Zeng et al.22 2014 N
Mean = 57.1 
(AMT) vs. 54.0 
(control)
14 (70%) 10 10 0 10 0 0 0




AMT AMT technique Severity of  ulcer$ Follow-up (months) COI
Arya et al.21 < 20/400 = 80% (AMT) versus 65% (control) NR Overlay (single layer)
2–5 mm = 60% (AMT) 
versus 45% (control) 3 N
Li et al.33 < 20/200 = 44% (AMT) versus 48% (control) 2 days Overlay (single or double layer) NS 1 N
Tabatabaei 
et al.20
Mean = 1.7 (AMT) versus 1.8 
(control) 2–5 days Inlay (double layer)
Mean = 26  mm2 (AMT) 
versus 27  mm2 (control) 6 N
Zeng et al.22 Median = 1.0 (AMT) versus 1.0 (control) NR Overlay (single layer)
Mean = 7 mm (AMT) 
versus 7 mm (control) 1 N
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the AMT group and 10.0–32.0% in the SAT group. Such heterogeneity was likely related to the variations in the 
patient cohort, types and severity of IK, and the standard treatment regimen employed among different studies. 
For each specific complication, adjuvant AMT group had a slightly lower risk than the SAT alone group in terms 
of worsening of IK requiring secondary debridement (0–10% vs. 0–20%), secondary glaucoma (4% vs. 36%), and 
corneal perforation requiring either corneal gluing or tectonic keratoplasty (0–26.5% vs. 10–32%). The quality of 
evidence was downgraded due to high risk of bias and imprecision. The follow-up duration was variable across 
studies, ranging from 1 to 6 months. One RCT (n = 50 eyes with fungal keratitis) reported the risk of second-
ary glaucoma, which was 4% (n = 1 eye) in the AMT group and 36% (n = 9 eyes) in the SAT group (p = 0.011)30. 
According to the CONSORT reporting of harms guidance, all four RCTs were judged to be of inadequate quality 
as the severity of adverse events and clinical sequalae were not clearly  described25–27,29.
Subgroup analysis based on the type of IK. There were insufficient RCTs to perform subgroup analysis 
between bacterial and fungal keratitis outcomes. In view of the limitation, pooled estimates on time to complete 
corneal healing and adverse events were assessed based on RCTs and NCRSs. Pooled estimates of the time to 
complete corneal healing showed that adjuvant AMT expedited the time to complete corneal healing in bacte-
rial keratitis (MD − 2.42 days; 95% CI − 4.53 to − 0.32; p = 0.02) and fungal keratitis (MD − 6.90 days; 95% CI 
− 11.58 to − 2.21; p = 0.004; Table 4). In terms of the risk of adverse events, the pooled estimates demonstrated 
that adjuvant AMT did not significantly influence the risk of adverse events in bacterial keratitis (RR 0.83; 
95% CI 0.45–1.54), fungal keratitis (RR 0.28; 0.05–1.65), and mixed bacterial/fungal keratitis cohorts (RR 1.50; 
0.28–8.04; Table 4).
Subgroup analysis of the outcomes based on large non-comparative case series (n ≥ 5 eyes) is summarized 
in Table 5. Studies that reported the pooled results with no distinction made to the underlying microorganisms 
were excluded from the subgroup analysis. Based on these case series, complete corneal healing rate was 92.6% 
(113/122) in bacterial keratitis, 80.0% (96/120) in fungal keratitis, 93.8% (137/146) in herpetic keratitis, in 77.8% 
(7/9) Acanthamoeba keratitis, 81.8% (9/11) in mixed bacterial and fungal infection, and 100% (4/4) in mixed 
bacterial and herpetic infection.
Discussion
To the best of our knowledge, this study represents the most up-to-date systematic review and meta-analysis 
examining the effectiveness and safety of adjuvant AMT for treating IK. The use of AMT for ocular diseases dates 
back to the early twentieth  century57. However, the procedure was not commonly performed until 1990s where 
Batlle and Perdomo demonstrated the wound healing property of AM, reinvigorating the interest of utilising 
AMT for ocular surface  disease8. The use of AMT for ocular surface reconstruction was subsequently popular-
ized by Kim and  Tseng58 using glycerin-preserved AM. Although AMT has since been performed to treat a wide 
array of ocular surface diseases, high-quality evidence of using AMT in treating active IK remains limited. So far, 
there has only been one systematic review that had partially examined the benefit of AMT in  IK24. The systematic 
review included 17 studies (n = 390 eyes) and examined the healing rate and visual improvement rate after AMT 
in either infectious or non-infectious corneal ulcers. While the review showed that AMT was effective in treating 
IK, it did not answer a very important clinical question, which is whether adjuvant AMT provides any additional 
benefit or risk during the management of IK, in addition to standard antimicrobial treatment. In addition, the 
review did not capture 3 RCTs that were identified in our systematic review, rendering the evidence of their find-
ings uncertain. Furthermore, the effect of AMT has not been examined in the context of the types of organisms.
Summary of main findings. In this systematic review, we included a total of 28 studies (n = 861 eyes), 
encompassing four RCTs with 209 eyes and 24 non-RCTs with 657 eyes. Among the RCTs, the majority of the 
included eyes were either affected by bacterial keratitis or fungal keratitis, with only 6 eyes being affected by 
mixed bacterial and fungal keratitis. None of the RCTs examined the effect of adjuvant AMT in herpetic or 
Acanthamoeba keratitis. Based on the meta-analysis of three RCTs, we demonstrated that early adjuvant AMT 
shortened the time to complete corneal healing by approximately 4 days when compared to SAT alone. In addi-
tion, it was shown that IK patients treated with adjuvant AMT achieved 0.26 logMAR (equivalent to 2–3 Snellen 
lines) better UDVA at 1 month follow-up compared to SAT alone. No evidence of difference was noted in terms 
of the risk of adverse events. Furthermore, other beneficial effects such as better CDVA and less corneal vascu-
larization were shown in the adjuvant AMT group.
The observed beneficial effects in the adjuvant AMT group are likely attributed to the dual antimicrobial 
and anti-inflammatory properties of  AMT8,16. The plausible mechanisms of antimicrobial effect of AMT in IK 
are at least twofold. First, the antimicrobial activity is directly linked to the presence of various antimicrobial 
components, including lysozyme, transferrin, and immunoglobulin, in the amniotic  fluid8,59. Second, studies 
have shown that AM could serve as an effective antibiotic reservoir when used in combination with antibiotics 
and provide sustained drug  delivery60. Furthermore, AM has been shown to exhibit anti-inflammatory func-
tion via regulation of T-cell function and secretion of anti-inflammatory antagonists, including IL-1ra, sTNF, 
and VEGF-R61,62. This anti-inflammatory property will have a long-term beneficial effect on the cornea, hence 
vision, as persistent corneal vascularization could negatively affect the vision, either directly via encroachment 
on the visual axis or indirectly via lipid keratopathy where exudation of lipid and inflammatory cells extends 
to the visual  axis63. Moreover, it increases the risk of graft rejection should corneal transplantation needs to be 
carried out to restore the optical clarity of the  cornea63,64.
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Authors Year Study design Total eyes (AMT)
Total eyes 
(control)
Causative organisms (in AMT group)
Severity of  ulcer$BK FK VK AK MK NSK
Kheirkhah et al.23 2012 NRCS 14 11 14 Mean = 32% (AMT) versus 33% (control)
Li et al.34 2014 NRCS 53 45 53 Not reported
Naeem et al.35 2004 NRCS 34 34 34 > 3 mm
Altay et al.36 2016 Case series 84 – 42 42 3 mm
Berguiga et al.37 2013 Case series 5 – 1 4 Central, deep ulcer/perforation (< 2 mm)
Bourcier et al.38 2004 Case series 6 – 6 Stromal lesions
Chen et al.39 2006 Case series 23 – 12 11 2–13 mm; > 50% depth to perforation
Chen et al.40 2002 Case series 6 – 6
Mean = 29  mm2, depth of 
25–33% (50%), descem-
etocele (50%)
Eleiwa et al.41 2020 Case series 5 – 5 Perforated corneal ulcer (3–5 mm)
Eraslan Yusufoglu 
et al.42 2013 Case series 46 – 21 25
Paracentral and central 
ulcer; depth of > 50% in 
viral (56%) and bacterial 
(33%) cases
Fu et al.43 2012 Case series 35 – 35 Median = 3–5 mm
Gicquel et al.44 2007 Case series 12 – 12 Mean = 5 mm
Hoffmann et al.45 2013 Case series 12 – 3 5 4 4–20mm
2, depth of 
10–90%
Kim et al.46 2001 Case series 21 – 9 2 7 3 Not reported
Li et al.47 2010 Case series 18 – 18  < 5 mm (67%), > 5 mm (33%), perforation (6%)
Mohan et al.48 2014 Case series 28 – 28 Not reported
Rao et al.49 2012 Case series 21 – 21 Not reported
Shi et al.50 2007 Case series 15 – 15 20–45mm
2, depth of 
20–33%
Spelsberg et al.51 2008 Case series 12 – 12 –
Wan &  Huo52 2010 Case series 35 – 9 20 6 Not reported
Wu et al.53 2013 Case series 18 – 18 1–7 mm
Xie et al.54 2014 Case series 19 – 19 3–6 mm
Yildiz et al.55 2008 Case series 14 – 14 Not reported
Zhang et al.56 2010 Case series 26 – 26 Median = 3–6 mm; 5 perforation
Authors Preop vision* Time to AMT AMT technique**
Combined with 
SAT
Outcomes (i.e. healing rate and 
time) Adverse event*** Postop vision* Follow-up (months)
Kheirkhah et al.23 2.0 (AMT) versus 2.0 (control) 2–3 days Overlay (Single) Y
Complete healing = 100%,
Mean healing time = 13 days (AMT) 
versus 16 (control)
None Mean = 0.5 (AMT) versus 0.7 (control) 11
Li et al.34 0.6 Not reported Inlay Y Mean healing time = 23 days (AMT) and 35 days (control) Not reported
Mean = 0.3 (AMT) versus 0.4 
(control) 2
Naeem et al.35 Not reported Not reported Not reported Y Complete healing = 96% (AMT) versus 30 (87%) (control) Not reported Not reported 2
Altay et al.36 Majority ≤ 1.0 2–5 days Overlay (Single or double) Y
Complete healing = 100% (BK) and 
95% (VK),
Mean healing time = 19 days
5% (VK) Improved in vision =  > 50% (BK); 2% (VK) 15
Berguiga et al.37 Mean = 1.0 7 days Mixed (Multiple) Y Complete healing = 100% (BK) and 75% (VK) 25% (VK) Improved in 40% cases 15
Bourcier et al.38 All ≤ CF Not reported Inlay or overlay (Single–multiple) Y Complete healing = 67% None Improved in 50% 14
Chen et al.39 CF–LP Not reported Inlay (Single or double) Y
Complete healing = 87%,
Mean healing time = 16 days 13% 20/20-LP 21
Chen et al.40 HM–LP 21 days Inlay (Single) Y Complete healing = 83%,Mean healing time = 9 days 17% Improved in 83% 13
Eleiwa et al.41 Median = CF 12 days Inlay (Double) Y Complete healing = 100%,Mean healing time = 26 days None Median = 0.3 14
Eraslan Yusufoglu 
et al.42 Median =  ≤ 20/200 Not clear Overlay (Double) Y
Complete healing = 100% (BK), 
88% (VK),
Mean healing time = 23 days
12% (VK) Improved in 57% (BK) and 8% (VK) 12
Fu et al.43 Median =  < 20/200 Not reported Overlay (Double) Y Complete healing = 94%,Mean healing time = 14 days 3% Improved in 94% 12
Gicquel et al.44 Median =  ≤ 6/60 2 days Overlay or mixed (Single–multiple) Y
Complete healing = 100%,
Mean healing time = 26 days None Median = 20/40 8
Hoffmann et al.45 Median = 20/20,000 Not reported Mixed (Multiple) Y Complete healing = 83%,Mean healing time = 24 days 17% Median = 20/200 22
Kim et al.46 20/40—LP Not reported Inlay or overlay (Single–multiple) Y Complete healing = 100% None Improved in 76% 18
Li et al.47 ~ 20/120 ~ 1 week Overlay (Double) Y Complete healing = 100% None Improved in 78% 3–18
Mohan et al.48 < 20/200 4 weeks Mixed (Multiple) Y Complete healing = 75% 25% Improved in 7% 6
Rao et al.49 Not mentioned ~ 2 weeks Mixed (Multilayer) Y Complete healing = 76% 10% Not reported 3
Shi et al.50 Median = 20/400 2 weeks Overlay (Multiple) Y Complete healing = 100%,Mean healing time = 15 days None Median = 20/40 Improved in 93% 9
Spelsberg et al.51 Median =  < 6/60 Not reported Inlay (Single) Y Complete healing = 75%,Mean healing time = 25 days 25% Improved in 8% 7
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Although the benefit of AMT in herpetic keratitis has not been ascertained in RCTs, our systematic review 
(based on large case series) showed that it enabled a high rate (94%) of complete corneal healing. Herpetic 
keratitis, particularly the necrotizing form, is a potentially sight-threatening condition that is difficult to treat 
 clinically65. It is also notoriously known to be associated with neurotrophic keratopathy, which results in delay 
in corneal  healing65,66. Therefore, AMT serves as a useful adjunct treatment in this clinical circumstance in view 
of its dual anti-viral and wound healing  properties67,68. On the other hand, only two case series have reported 
the use of AMT in Acanthamoeba keratitis, albeit good effect was observed. The broad-spectrum antimicrobial 
activity of AMT (observed in our systematic review) against a wide range of microorganisms is particularly 
beneficial in the management of IK as polymicrobial keratitis is a relatively common entity, which often poses 
significant diagnostic and therapeutic  challenges4,5,69. Based on large case series, adjuvant AMT has been shown 
in our review to be an effective treatment for mixed bacteria/fungal keratitis (82% complete healing; n = 9/11) 
and mixed bacterial/herpetic keratitis (100% complete healing; n = 4/4).
A number of studies have also demonstrated that AMT, when employed as multi-layer, could effectively treat 
IK with threatened or actual corneal perforation (up to 5 mm)35,37,43,52. Studies have demonstrated that multi-
layer AMs can promote re-epithelialization of the cornea and integrate with the corneal stroma, with progressive 
repopulation of AM by cornea stroma-derived cells, ultimately resulting in corneal healing and  thickening70. 
This approach helps obviate the need for an emergency therapeutic keratoplasty, which is known to be associated 
with high risk of graft failure (in the setting of active inflammation) and recurrence of  infection69,71,72. It would 
also help reduce the burden on the availability of donor corneas, which have been significantly affected by the 
recent COVID-19  pandemic73.
Overall completeness and applicability of evidence. This study represents the most up-to-date sys-
tematic review and meta-analysis specifically examined the effectiveness and safety of adjuvant AMT in manag-
ing all types of IK. The four RCTs included primarily bacterial and fungal keratitis cases, therefore the outcome 
of the meta-analysis should be interpreted in the context of these types of infection. All RCTs were completed 
without any significant drop out and there was no concern with the safety of AMT.
The reporting and categorization of the baseline severity of IK was considerably variable among the RCTs. 
Two studies included corneal ulcers with a mean diameter of 5–7 mm (severe disease)25,27, one study included 
mainly moderate (2–5 mm in diameter) and severe (> 5 mm in diameter) ulcers, and one did not report the 
baseline severity. Such heterogeneity highlights the need for standardized reporting and a core outcome set in 
the future clinical trials related to IK. Of the three RCTs that reported the baseline severity of IK, the majority 
of the included participants/eyes were affected by moderate-to-severe IK, suggesting that adjuvant AMT would 
be useful for this group of patients. Future studies examining the effectiveness and safety of adjuvant AMT in 
mild-to-moderate IK would be required before being routinely applied in clinical practice.
Another aspect that was not examined in this systematic review is the effects of different surgical tech-
niques and types of AMT on the clinical outcomes. In clinical practice, a number of AMT techniques have been 
described. It can be used as a patch (or overlay) where an AM that is transplanted to cover the ocular surface, 
allowing the host corneal epithelium to regenerate under the AM. It can also be used as graft (or inlay) where 
a smaller AM is grafted over the corneal epithelial defect and act as a substrate for the host epithelium to grow 
over. Occasionally, a sandwich AMT technique, utilizing a mixture of overlay and inlay, is performed to facilitate 
the regeneration of host epithelium between the  AMs16. In addition, various forms of AMs, either fresh form, 
cryopreserved, lyophilized (freeze-dried), or air-dried AM, have been used, with comparable clinical efficacy 
observed amongst  them16. While studies have shown the varying effects of preservation method on the struc-
tural and functional properties of AMs, strong clinical evidence is lacking in the literature. Cryopreserved AMs, 
depending on the duration of the preservation, have been shown to possess no or less viable cells compared to 
fresh, freeze-dried or vacuum-dried AM, which have more viable cells with proliferative  capability16,74. On the 
other hand, some studies have demonstrated that lyophilization of the AMs may lead to a greater reduction in 
the growth factors compared to cryopreservation. Preclinical studies observed similar efficacy in terms of heal-
ing activity between cryopreserved and freeze-dried AMs, supporting the use of both types of AMs in clinical 
 setting75,76. In our systematic review, the three RCTs included in the meta-analysis for time to complete healing 
Authors Preop vision* Time to AMT AMT technique**
Combined with 
SAT
Outcomes (i.e. healing rate and 
time) Adverse event*** Postop vision* Follow-up (months)
Wu et al.53 > 20/200 = 7 (39%) 1–3 days Mixed (Multiple) Y Complete healing = 100%,Mean healing time = 17 days None > 20/200 = 72% 4
Xie et al.54 Mean = 1.3 1 week Mixed (Double) Y Complete healing = 42%,Mean healing time = 36 days Not reported Mean = 0.9 3
Yildiz et al.55 Not reported Not reported Overlay (Single) Y Complete healing = 100% Not reported Not reported 22
Zhang et al.56 Not reported Not reported Mixed (Double) Y Complete healing = 81% 8% Improved in 80% 3–36
Table 2.  Summary of all clinical studies (excluding RCTs) evaluating the use of amniotic membrane 
transplantion (AMT) for infectious keratitis. BK bacterial keratitis, FK fungal keratitis, VK viral keratitis, 
AK acanthamoeba keratitis, MK mixed keratitis, NSK non-specified keratitis, SAT standard antimicrobial 
treatment, NRCS non-randomized controlled studies, CF counting fingers, HM hand movement, PL perception 
of light. $ Severity of the corneal ulcer is presented either in maximum linear diameter (mm), in area  (mm2) 
or in percentage of total cornea (%). *Vision is presented in either Snellen vision or logMAR vision. **AMT 
technique is categorized by the type of grafting (inlay as graft vs. overlay as patch vs. mixed inlay/overlay) 
and number of layers (single layer vs. double layer vs. multiple layers). ***Adverse event was defined as 
uncontrolled/worsening infectious keratitis requiring tectonic keratoplasty or evisceration.
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outcome, one RCT employed cryopreserved AMT, another RCT utilized freeze-dried AMT and the remainder 
did not report the preservation method used. Therefore, it is not possible to perform a head-to-head comparison 
between each type of AM due to limited studies, but the overall effect of either type was positive.
Quality of evidence and potential biases in the review. Similar outcome reporting in the included 
RCTs has enabled the meta-analysis, which demonstrated the value of adjuvant AMT in expediting complete 
Figure 2.  Risk of bias assessment of all included randomized controlled trials (RCTs) based on revised risk 
of bias tool (RoB 2). (A) A summary of review authors’ judgements about each risk of bias item presented as 
percentages across all included RCTs. (B) Review authors’ judgements about each risk of bias item presented 
individually for all included RCTs.
Table 3.  GRADE summary of findings for various treatment outcomes of adjuvant amniotic membrane 
transplantation for infectious keratitis. GRADE Working Group grades of evidence. High certainty: We are 
very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are 
moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is 
limited: The true effect may be substantially different from the estimate of the effect. Very low certainty: We 
have very little confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect. Explanations. a High risk of bias due to lack of randomization and allocation concealment in 
≥ 50% of the included studies. b Potential risk of bias due to the lack of blinding in participants and assessors. 
c The total number of participants is less than the number generated by a conventional sample size calculation. 
d There are few events and the confidence interval includes appreciable benefit and harm. e Differences in 
final follow-up duration. CI confidence interval, MD mean difference, RR risk ratio, UDVA uncorrected-
distance-visual-acuity, CDVA corrected-distance-visual-acuity. *The risk in the intervention group (and its 
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).
Adjuvant amniotic membrane transplantation (AMT) compared to standard antimicrobial treatment (SAT) for infectious keratitis
Patient or population: Infectious keratitis 
Intervention: Adjuvant amniotic membrane transplantation (AMT)
Comparison: Standard antimicrobial treatment (SAT)
Outcomes
Anticipated absolute effects* (95% CI)
Relative effect (95% CI) No of eyes (studies)
Certainty of the evidence 
(GRADE)Risk with SAT Risk with AMT
Time to complete healing (days) 10.2–30.7 days MD 4.08 days shorter (6.27 shorter to 1.88 shorter) – 169 (3 RCTs)
⨁◯◯◯
VERY  LOWa,b,c
UDVA (logMAR) at 1 months 1.27–1.88 logMAR MD 0.26 logMAR better (0.50 better to 0.02 better) – 119 (2 RCTs)
⨁◯◯◯
VERY  LOWa,b,c
CDVA (logMAR) at 6 months 1.55 logMAR MD 0.43 logMAR better (0.68 better to 0.17 better) – 99 (1 RCT)
⨁⨁◯◯
LOWb,c
Size of corneal scar  (mm2) at 
6 months 22.8  mm
2 MD 5.17  mm2 smaller (7.53 
smaller to 2.8 smaller) – 99 (1 RCT)
⨁⨁◯◯
LOWb,c
Corneal vascularization (%) at 
6 months 7%
MD 4% smaller (6 smaller to 3 
smaller) – 99 (1 RCT)
⨁⨁◯◯
LOWb,c
Adverse events at 1–6 months 23 per 100 18 per 100 (11–32) RR 0.80 (0.46–1.38) 209 (4 RCTs) ⨁◯◯◯VERY  LOWa,b,c,d,e
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corneal healing, reducing corneal vascularization and potentially achieving better visual outcome. However, two 
RCTs have some concerns on the risk of bias and another two RCTs have high risk of bias. Due to the lack of 
information in the randomization process, lack of blinding, and under-powered sample size. In addition, none 
of the RCTs were prospectively registered with any clinical trial database, which limits the assessment of selective 
reporting of the outcomes.
Of all four RCTs, only Tabatabaei et al.25 conducted a sample size calculation based on the anticipated differ-
ence in the size of corneal scar (mean effect size of 4  mm2, standard deviation of 6  mm2, and power of 90%), which 
yielded a sample size of 48 eyes in each group. However, it is noteworthy to mention that size of corneal scar is 
not a routine outcome measure for IK. Based on the findings of our systematic review, an appropriate sample size 
(using time to complete corneal healing as the main outcome measure) is estimated to be at approximately 200 
participants/eyes (based on a mean difference or effect size of 4.08 days, standard deviation of 14.56 days, power 
of 80% and alpha of 5%). This sample size is also supported by some previous RCTs examining the effectiveness 
of therapeutic CXL (or PACK-CXL) for IK, where an appropriate sample size was estimated at around 200–250 
participants, using time to complete corneal healing as the main outcome  measure10,77. This large sample size 
would then potentially control for various potential confounding variables that could affect the time to complete 
healing, including the demographic factors, initial size and severity of the corneal ulcer, types of organisms, and 
underlying comorbidity (e.g. diabetes).
Figure 3.  Summary of the meta-analysis (forest plot) comparing the efficacy between adjuvant amniotic 
membrane transplantation (AMT) plus standard antimicrobial treatment (SAT) and SAT alone in eligible 
randomised controlled trials, in terms of: (A) time to complete corneal healing; (B) uncorrected-distance-visual-
acuity; and (C) risk of adverse events.
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Table 4.  Pooled estimates of the time to complete corneal healing and risk of adverse events between adjuvant 
amniotic membrane transplantation (AMT) and standard antimicrobial treatment (SAT) alone based on 
comparative studies, including randomized controlled trials (RCTs) and non-randomized controlled studies 
(NRCS). A negative MD value indicates that adjuvant AMT group has a shorter time to complete corneal 
healing compared to SAT alone group. IK infectious keratitis, CI confidence interval.
IK Cohort No. of studies Types of studies No. of eyes Pooled estimates (95% CI)
Time to complete corneal healing (estimates presented in mean difference, MD)
Bacterial 2
1 RCT 20




168 − 6.90 (− 11.58 to − 2.21)
1  NRCS34





Fungal 2 2  RCTs22,33 70 0.28 (0.05–1.65)




Table 5.  Summary of the healing rate and treatment failure of amniotic membrane transplantation (AMT) in 
large case series (N > 5 eyes) based on the types of causative microorganisms.
Authors Year Numbers Complete healing Healing time (days) Adverse events
Bacterial keratitis
Altay et al.36 2016 42 42 (100%) 19 0 (0%)
Berguiga et al.37 2013 1 1 (100%) – 0 (0%)
Chen et al.40 2002 6 5 (83%) 9 1 (17%)
Eraslan Yusufoglu et al.42 2013 21 21 (100%) 22 0 (0%)
Gicquel et al.44 2007 12 12 (100%) 26 0 (0%)
Hoffmann et al.45 2013 3 2 (67%) 31 1 (33%)
Kim et al.46 2001 9 9 (100%) – 0 (0%)
Mohan et al.48 2014 28 21 (75%) – 7 (25%)
Fungal keratitis
Chen et al.39 2006 12 11 (92%) 4–26 1 (8%)
Eleiwa et al.41 2020 5 5 (100%) 26 0 (0%)
Fu et al.43 2012 35 33 (92%) 14 1 (3%)
Kim et al.46 2001 2 2 (100%) – 0 (0%)
Rao et al.49 2012 21 16 (76%) – 2 (10%)
Xie et al.54 2014 19 8 (42%) 36 Not reported
Zhang et al.56 2010 26 21 (81%) – 2 (8%)
Herpetic keratitis
Altay et al.36 2016 42 40 (95%) 19 2 (5%)
Berguiga et al.37 2013 4 3 (75%) – 1 (25%)
Eraslan Yusufoglu et al.42 2013 25 22 (88%) 22 3 (12%)
Hoffmann et al.45 2013 5 5 (100%) 21 0 (0%)
Kim et al.46 2001 7 7 (100%) – 0 (0%)
Li et al.47 2010 18 18 (100%) – 0 (0%)
Shi et al.50 2007 15 15 (100%) 15 0 (0%)
Spelsberg et al.51 2008 12 9 (75%) 25 3 (25%)
Wu et al.53 2013 18 18 (100%) 17 0 (0%)
Acanthamoeba keratitis
Bourcier et al.38 2004 6 4 (67%) – 0 (0%)
Kim et al.46 2001 3 3 (100%) – 0 (0%)
Mixed bacterial and fungal keratitis
Chen et al.39 2006 11 9 (82%) 7–23 2 (18%)
Mixed bacterial and herpetic keratitis
Hoffmann et al.45 2013 4 4 (100%) 22 0 (0%)
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Another important bias, which is a common issue in surgical trial, is related to the difficulty in blinding (or 
masking) the participants and the  surgeons78,79. This is evident in our systematic review where none of the RCTs 
had implemented or reported any measure to ensure the masking of participants or surgeons, which could poten-
tially lead to risk of bias. In a trial, masking can be introduced to 5 groups of individuals, including participants, 
surgeons, data collector, outcome adjudicators and data analysts. While it is always possible to mask the latter 
three groups (i.e. data collectors, outcome adjudicators and data analysts), masking of the participants or surgeons 
may not always be possible, depending on the surgical intervention and design. For instance, in AMT trial, it 
would have been difficult to mask the patients or surgeons as the patients would have known that an AMT has 
been performed (unless a sham surgery is performed) and the surgeons would have seen the physical presence of 
the AM postoperatively. However, masking the other 3 groups of individuals could reduce the bias. As fewer than 
10 studies were eligible for inclusion, we were unable to use a funnel plot to identify possible publication bias.
In conclusion, this systematic review and meta-analysis demonstrated the benefit of early adjuvant AMT in 
accelerating corneal healing and improving visual outcome in moderate-to-severe bacterial and fungal keratitis. 
However, further adequately powered and well-designed RCTs are required to ascertain the true potential of 
adjuvant AMT in treating active IK, particularly herpetic and Acanthamoeba keratitis. Future standardization 
of the baseline assessment and core outcome set for clinical trials related to IK would also be invaluable.
Methods
Protocol registration. The systematic review protocol was registered with PROSPERO (registration num-
ber: CRD42020175593) and The Joanna Briggs Institute of Evidence  Synthesis80.
Data sources and search methods. Two authors (D.S.J.T and C.H.) searched MEDLINE (January 1950 
to November 2020), EMBASE (January 1980 to November 2020), Cochrane Central Register of Controlled Trials 
(CENTRAL), ISRCTN registry (www. isrctn. com/ editA dvanc edSea rch), US National Institutes of Health Ongo-
ing Trials Register ClinicalTrials.gov (http:// clini caltr ials. gov) and World Health Organization (WHO) Interna-
tional Clinical Trials Registry Platform (ICTRP) (www. who. int/ ictrp) for primary research related to AMT for 
IK. There was no date or language restriction in the search for trials. Electronic databases were first searched 
on 01 March 2020, followed by a final update on 01 November 2020. The bibliographies of the included articles 
were reviewed for any additional eligible articles. Key words used were “amnion”, “amniotic membrane”, “corneal 
ulcer”, “corneal infection”, “infectious keratitis”, and “microbial keratitis”. Search strategies for MEDLINE and 
EMBASE are provided in the Supplemental Table S1.
Study selection. All clinical studies, encompassing RCTs, NRCSs and case series (n ≥ 5 eyes), related to 
AMT for IK were included as few RCTs were anticipated. The analysis was conducted at two levels; (1) a meta-
analysis of all eligible RCTs and (2) a systematic review of all clinical studies, including NRCSs and case series. 
All types of IK, including bacterial, fungal, viral, parasitic or mixed infection, were included in this review. Stud-
ies that evaluated cases of non-infectious keratitis, other types of surgical interventions, or AMT used for non-
antimicrobial purpose were excluded from this study. Small case series (N < 5 eyes), reviews, published abstracts, 
laboratory and animal studies were also excluded. For the meta-analysis, the intervention group included cases 
of IK that were treated by AMT and SAT whereas the control group included cases of IK that were treated with 
SAT alone. There was no restriction applied to the published language, location or setting of the study, or patient 
demographic factors. This study conformed to the Preferred Reporting Items for Systematic reviews and Meta-
Analysis (PRISMA) guideline (see Supplementary Table S2)81.
Data extraction. A web application designed for systematic reviews, Rayyan (Qatar)82, was used to help 
collate the potential studies and expedite the initial screening of abstracts and titles. The titles and abstracts 
obtained from the searches were independently screened by two authors (D.S.J.T. and C.H.) to include stud-
ies that fulfilled the eligibility criteria. The authors then independently assessed the full-text version of all the 
selected articles and extracted data onto a standardized data collection form for qualitative review. The extracted 
data included the authors, year of publication, sample size, types of interventions, types of causative microorgan-
isms, outcomes and  complications80. Discrepancies were resolved by group consensus if consensus could not be 
reached.
For the meta-analysis, the following information were extracted from the included RCTs and entered into 
RevMan (Review Manager 5.4)  software80,83:
(1) Study characteristics: Year of publication, country of study, prospective registration of clinical trials in 
a publicly accessible database, sample size, eligibility criteria, demographic factors, diagnostic criteria, 
method of randomization, method of masking, number of study arms, number of participants, types and 
techniques of AMT, types of comparators, source of funding, and any potential conflict of interest. Types 
of AMT were divided based on the preservation technique, which included fresh, cryopreserved, freeze-
dried (or lyophilization), air-dried and others. Surgical techniques were categorized based on the number 
of AMT (i.e. single vs. double vs. multiple layers) and the type of transplant (i.e. overlay/patch vs. inlay/
graft vs. mixed overlay and inlay).
(2) Outcomes: Primary and secondary outcomes (including the time point at which the outcomes were 
assessed), intra- and post-operative complications, adverse events, need for secondary surgery, duration 
of follow-up, and rate of loss to follow-up.
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Outcome measures. For the meta-analysis, the primary outcome measure was the time to complete cor-
neal healing (defined as complete corneal re-epithelialization and clearance of infiltrate and hypopyon; days) 
and the secondary outcome measures included the corrected-distance-visual-acuity (CDVA; logMAR) and 
uncorrected-distance-visual-acuity (UDVA; logMAR) at final follow-up (1–6 months), size of corneal ulcer (at 
1–6 months), extent of corneal vascularization, and risk of adverse events (defined as worsening IK and/or cor-
neal melt/perforation requiring gluing or tectonic/therapeutic keratoplasty or evisceration) at final follow-up 
(1–6 months). These outcome measures were similarly used in our previous systematic review and meta-analysis 
in examining the effectiveness and safety of adjuvant PACK-CXL for  IK10. Relevant data of all included studies 
were summarized and reported.
Continuous variables such as time to complete corneal healing, UDVA, CDVA, and size of corneal epithelial 
defect and infiltrate, were presented as mean with standard deviation (SD). In studies that reported median and 
interquartile range, the means and SDs were estimated using formulas reported by Wan et al.84 and the Cochrane 
Handbook  estimator85. Dichotomous variable such as risk of adverse events was defined by the number of eyes 
with adverse events.
Assessment of risk of bias. Risk of bias was assessed by two authors (D.S.J.T. and C.H.) independently 
and any disagreement was adjudicated by group consensus. Included RCTs were assessed for sources of system-
atic bias using the revised Cochrane risk of bias tool (RoB 2 tool)86. The review authors were not masked to the 
authors of the studies during this assessment. A judgement of risk of bias as ‘high risk’, ‘some concern’, or ‘low 
risk’ was made for the following domains: (1) randomization process; (2) deviations from intended interven-
tions; (3) missing outcome data; (4) measurement of the outcome; and (5) selection of the reported  result86. 
NRCSs were assessed for risk of bias using the ROBINS-I  tool87 against seven domains; the worst judgement in 
any of the domains was used as the overall risk of bias.
Measure of treatment effect. Dichotomous data were measured as risk ratios (RRs) with 95% confidence 
intervals (CI) and continuous data as mean differences (MDs) with 95%  CI80,88. The unit of analysis was the eye 
as the patient might have different causes of infection and treatment in each eye. There was no issue with the unit 
of analysis in the included RCTs. The review was conducted based on the available data from the trials. When 
data were unavailable but the level of missing data and reasons for missing data in each group were similar, data 
were analyzed even when intention-to-treat (ITT) analysis was not performed.
Assessment of heterogeneity. The heterogeneity of the RCTs and NRCSs was checked by careful review 
of the full-text, assessment of forest plots and examination of the  I2 value with its confidence interval. The overall 
characteristics of the studies, in particular the types of participants, causes of IK and types of interventions were 
examined to assess the extent to which the studies were similar enough to make pooling study results  sensible80. 
The results of forest plots were reviewed for consistency of the size and direction of effects.  I2 values greater than 
50% were considered indicative of substantial heterogeneity and meta-analysis could not be conducted due to 
inconsistency of effect  estimates85. Random-effects model was used for the meta-analysis as some degree of het-
erogeneity will always exist due to clinical and methodological differences of the  studies80. The  Chi2 p value was 
also considered as this has a low power when the number of studies were few. A p value of < 0.1 was considered 
statistically  significant85.
Data synthesis and analysis. A meta‐analysis was undertaken when there were sufficient similarities in 
the reporting of outcome  measures80. A random‐effects model in RevMan 5.4 was used in view of the expected 
heterogeneity across different studies. The Mantel–Haenszel method was employed for analysing the risk ratio 
(RR) of adverse events in view of the small expected number of  events80. If there was inconsistency between 
the results of individual studies such that a pooled result might not be a good summary of the individual trial 
results—for example, the effects were in different directions or  I2 > 50% and p < 0.1—the data were not pooled 
but described in narrative  format80,88. Where there was statistical heterogeneity the data were pooled when all the 
effect estimates were in the same direction, such that a pooled estimate would seem to provide a good summary 
of the individual trial results. Sensitivity analysis was performed by assessing the impact of including studies at 
high risk of bias for an outcome in one or more key  domains80. This was conducted by omitting each study in 
turn to examine the influence of individual studies (with high risk of bias) on the overall pooled estimate. A sum-
mary of findings is presented below including the assessment of the quality of the evidence for outcomes using 
the GRADE approach with GRADE Pro/GDT  software89. All RCTs were started with a rating of ‘high-quality’ 
evidence and were downgraded by one level for serious concerns (or by two levels for very serious concerns) 
regarding the risk of bias, inconsistency, indirectness, imprecision and publication bias. The quality of evidence 
of studies was graded by two assessors (D.S.J.T and C.H.) independently and any disagreement was adjudicated 
by group consensus.
Subgroup analysis based on the type of organisms. In addition to the meta-analysis, a subgroup 
analysis of the effectiveness and adverse events based on different types of organisms was performed. In view 
of the anticipated low number of RCTs, both experimental and quasi-experimental study designs including 
RCTs and NRCSs were included in the subgroup analysis. Descriptive case series were also reviewed for rare or 
uncommon adverse events. Pooled estimates of the time to complete corneal healing and risk of adverse events 
across comparative studies, including RCTs and NRCSs, were calculated. Causes of IK were categorized as bacte-
rial, fungal, viral, Acanthamoeba, or mixed infection.
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